PanamaTimes

Sunday, Jul 06, 2025

NFT of mRNA vaccine research to go on sale

NFT of mRNA vaccine research to go on sale

A new NFT digital asset from the University of Pennsylvania showcases pivotal mRNA research that could lead to life-changing vaccines for COVID-19 and beyond.
Dr. Drew Weissman, a physician and immunologist known for his groundbreaking contributions to RNA biology, and the RNA biochemist Dr. Katalin Kariko developed the modified RNA technology that became a foundational component of BioNTech/Pfizer and Moderna’s mRNA vaccines for COVID-19.

Now, 18 months later, “Vaccines for a New Era,” the University of Pennsylvania mRNA NFT — non-fungible token — will be released on July 15, a Christie’s press release said.

The digital asset includes a 3D model of the critical technologies that have enabled mRNA vaccines as well as research focused on the discovery and development of mRNA therapeutics for some of the world’s most deadly diseases.

The NFT also features a dynamic video that shows how mRNA-based COVID-19 vaccines work, including how the mRNA vaccine enters the body’s cells and stimulates an immune response.

The animated digital art demonstrates mRNA encoding of the SAR-CoV-2 spike protein encapsulated inside lipid nanoparticles and administered as a vaccine, providing protection from the SARS-CoV-2 virus that causes COVID-19 disease.

The NFT also includes an explainer, image copies of Penn-owned mRNA patent documents, and an original letter from Dr. Weissman.

The proceeds from the sale of the NFT will be used to further important research at Penn.

While much of the attention focused on how quickly COVID-19 vaccines were developed in response to the pandemic, Dr. Weissman said that it resulted from a career’s worth of research and dedication by him and many other scientists worldwide.

“I laugh because it’s a 25-year overnight success,” Dr. Weissman said.

Initially, he and Dr. Kariko struggled to secure funding for their critical research.

“‘It took over 10 years to get people to recognize the potential of modified mRNA technology for therapeutic and vaccine development,” he said. “But Kati and I weren’t just sitting in a room hoping; we never gave up. The data looked very promising. The feeling that it would someday work and be a useful technology in creating new therapies kept us going.”

Dr. Kariko and Dr. Weissman together discovered how to modify mRNA to significantly reduce its inherent inflammatory activity.

Dr. Weissman’s lab later developed a delivery technique to package the mRNA in fat droplets known as lipid nanoparticles. These advances contributed to mRNA becoming safer, more effective and more practical for use in vaccines.

When the DNA sequence for the coronavirus was released on Jan. 10, 2020, vaccine developers immediately began to use Dr. Weissman and Dr. Kariko’s modified mRNA technology.

“When we saw that it was a coronavirus, we knew it was the spike protein that would be targeted in a vaccine,” Dr. Weissman said.

The first modified mRNA vaccine for COVID-19 developed by BioNTech and Pfizer, which was initially found to prevent severe disease and death with exceptional efficacy, was an important milestone.

“As a physician, my career aim has always been to contribute to development of technologies and products that help people,” Dr. Weissman said. “So seeing these extremely positive results of the Phase 3 human trials for modified mRNA vaccines against SAR-CoV-2 was an incredible feeling,” he said.

“Art is really important in communicating scientific ideas to the public. It’s a way to introduce people to science, how it works, why it’s so exciting, and its future potential. The COVID-19 vaccine is just one of many potential future products that may benefit from the modified mRNA technology developed at Penn.”

Dr. Weissman and his colleagues are developing a variety of potential future vaccines and therapies, such as a pan-coronavirus vaccine to prevent future pandemics, a universal flu vaccine, as well as vaccines to prevent herpes and malaria, among others.

Dr. Weissman also highlighted the possibility of using mRNA in vaccines to prevent fatal allergies and for gene therapies to treat sickle cell anemia.

The sale of the University of Pennsylvania mRNA NFT: Vaccines for a New Era will run exclusively online from July 15-25.
Newsletter

Related Articles

PanamaTimes
0:00
0:00
Close
AI Raises Alarms Over Long-Term Job Security
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Brazilian Congress Rejects Lula's Proposed Tax Increase on Financial Transactions
Landslide in Bello, Colombia, Results in Multiple Casualties
Papa Johns pizza surge near the Pentagon tipped off social media before Trump's decisive Iran strike
Juncker Criticizes EU Inaction on Trump Tariffs
Minnesota Lawmaker Melissa Hortman and Husband Killed in Targeted Attack; Senator John Hoffman and Wife Injured
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
Sole Survivor of Air India Crash Recounts Escape
Coinbase CEO Warns Bitcoin Could Supplant US Dollar Amid Mounting National Debt
UK and EU Reach Agreement on Gibraltar's Schengen Integration
Israeli Finance Minister Imposes Banking Penalties on Palestinians
U.S. Inflation Rises to 2.4% in May Amid Trade Tensions
Trump's Policies Prompt Decline in Chinese Student Enrollment in U.S.
Global Oceans Near Record Temperatures as CO₂ Levels Climb
Trump Announces U.S.-China Trade Deal Covering Rare Earths
Smuggled U.S. Fuel Funds Mexican Cartels Amid Crackdown
Protests Erupt in Los Angeles with Symbolic Flag Burning
Trump Administration Issues New Travel Ban Targeting 12 Countries
Man Group Mandates Full-Time Office Return for Quantitative Analysts
JPMorgan Warns Analysts Against Accepting Future-Dated Job Offers
Builder.ai Faces Legal Scrutiny Amid Financial Misreporting Allegations
Japan Grapples with Rice Shortage Amid Soaring Prices
Goldman Sachs Reduces Risk Exposure Amid Market Volatility
HSBC Chairman Mark Tucker to Return to AIA as Non-Executive Chair
Israel Confirms Arming Gaza Clan to Counter Hamas Influence
Judge Blocks Trump's Ban on International Students at Harvard
Trump Proposes Travel Ban on 'Uncontrolled' Countries
Panama Port Owner Balances US-China Pressures
Trump Administration Accused of Obstructing Deportation Cases
Trump’s China Strategy Remains a Geopolitical Puzzle
Eurozone Inflation Falls Below ECB Target to 1.9%
Call for a New Chapter in Globalisation Emerges
Blackstone and Rivals Diverge on Private Equity Strategy
Mayor’s Security Officer Implicated | Shocking New Details Emerge in NYC Kidnapping Case
Bangkok Ranked World's Top City for Remote Work in 2025
Denmark Increases Retirement Age to 70, Setting a European Precedent
Netanyahu Accuses Western Leaders of 'Emboldening Hamas'
Escalating Trade Tensions and Market Reactions
OnlyFans Reportedly in Talks for $8 Billion Sale
JBS Gains Shareholder Approval for U.S. Stock Listing
Booz Allen Hamilton to Cut 2,500 Jobs Amid Federal Spending Reductions
Trump Signs Executive Orders to Accelerate Nuclear Energy Development
Harvard Temporarily Blocks Trump Administration's International Student Ban
Nippon Steel Forms Partnership with U.S. Steel, Headquarters to Remain in Pittsburgh
Trump Expands Tariff Threats to Apple and Samsung Devices
Oracle and OpenAI Plan $40 Billion Nvidia Chip Purchase for AI Data Center
Trump Threatens 50% Tariff on EU Goods, Markets React
The Daily Debate: The Fall of the Dollar — Strategic Reset or Economic Self-Destruction?
×